Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference - Seite 2
- Enrollment in the 12-week Phase 2a NASH trial is expected to conclude in the first quarter of 2019 allowing Enanta to report preliminary top line data in the third quarter of 2019.
- Enanta also expects to identify an FXR follow-on clinical candidate in 2019.
Webcast Information
Enanta’s presentation will take place on January 7, 2019 beginning at 4:30 p.m. Pacific Time. A live webcast of the presentation, as well as the question and answer breakout session that follows
the presentation, will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for approximately 60 days.
About Enanta
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment
of viral infections and liver diseases. Glecaprevir, a protease inhibitor discovered by Enanta, has been developed by AbbVie, and is now approved and sold in numerous countries as part of AbbVie’s
newest treatment for chronic hepatitis C virus (HCV) infection. This leading HCV regimen is sold under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Ongoing
royalties from the AbbVie collaboration are helping to fund Enanta’s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus
(RSV), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and hepatitis B virus (HBV). Please visit www.enanta.com for more information.
Lesen Sie auch
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including statements with respect to the prospects for Enanta’s further development of EDP-938, EDP-305 and EDP-314 for RSV, NASH/PBC and
HBV, respectively, and the prospects for additional royalties for Enanta from AbbVie’s sales of MAVYRET /MAVIRET (glecaprevir/pibrentasvir) regimen for HCV. Statements that are not historical facts
are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The
statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes
and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the development risks of early stage
discovery efforts in new disease areas in Enanta’s research and development efforts, such as RSV, NASH, PBC and HBV; Enanta’s revenues in the short-term are dependent upon the continued success of
AbbVie’s commercialization of its MAVYRET/MAVIRET regimen; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for HCV, NASH, PBC, RSV and
HBV; reimbursement actions affecting MAVYRET/MAVIRET or any competitive treatment for HCV; Enanta’s limited clinical development experience; Enanta’s need to attract and retain senior management
and key scientific personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and
other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Form 10-K for the fiscal year ended September 30, 2018 and other periodic reports filed more recently with the
Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of
this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.